

Special Issue

Image-Guided Adaptive Radiation Therapy (IGART): Advancing Precision Oncology

Message from the Guest Editors

As the field of radiation therapy continues to evolve, IGART represents one of the most transformative advancements, offering unprecedented precision in tumor targeting while sparing healthy tissues. This Special Issue aims to highlight recent innovations, clinical applications, and future directions of IGART. We are particularly interested in

- Advanced imaging techniques (CT, MR, PET/CT) and their integration with adaptive radiotherapy.
- Clinical outcomes of IGART in various cancer types.
- Computational models and algorithms for real-time adaptation.
- Overcoming challenges in implementing IGART in clinical practice.
- Cost-effectiveness and patient-centered approaches in adaptive radiation therapy.

Dr. Bin Cai

Dr. Murat Surucu

Guest Editors

Prof. Dr. An Liu

City of Hope National Medical Center, Duarte, CA, USA

Dr. Bin Cai

Department of Radiation Oncology, UT Southwestern Medical Center, Dallas, TX, USA

Dr. Murat Surucu

Department of Radiation Oncology–Radiation Physics, Stanford University School of Medicine, Stanford, CA, USA

Deadline for manuscript submissions

30 June 2026



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/227135

Cancers

Editorial Office

MDPI, Grosspeteranlage 5

4052 Basel, Switzerland

Tel: +41 61 683 77 34

cancers@mdpi.com

mdpi.com/journal/

[cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers (ISSN 2072-6694) is an international, online journal addressing both clinical and basic science issues related to cancer research. The journal will continue its open access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)